Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylene Glycol SCHEMBL28493726 | 0.96 | ALDH1A1 (0.52) | ALDH1A1FKBP5TDP1 | |
| Imidazole SCHEMBL7573227 | 0.86 | — | — | |
| Butanol SCHEMBL12471635 | 0.85 | ALDH1A1 (0.54) | ALDH1A1FKBP5 | |
| Glycerin SCHEMBL23579100 | 0.84 | ALDH1A1 (0.59) | ALDH1A1FKBP5 | |
| Glycerin SCHEMBL231119 | 0.84 | ALDH1A1 (0.59) | ALDH1A1FKBP5 | |
| Glycerin SCHEMBL23579221 | 0.84 | ALDH1A1 (0.59) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL28071722 | 0.84 | ALDH1A1 (0.65) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL28917506 | 0.82 | ALDH1A1 (0.62) | ALDH1A1FKBP5 | |
| Imidazole SCHEMBL4024594 | 0.82 | — | — | |
| Imidazole SCHEMBL17767371 | 0.82 | ALDH1A1 (0.50) | ALDH1A1FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971372-B1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMAIN CORP (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20170368190-A1 | Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same | PHARMAIN CORPORATION (US) | 2017-12-28 | — | — | US | disclosed |
| US-9737615-B2 | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | PharmalN Corporation (US) | 2017-08-22 | — | — | US | disclosed |
| US-20140154203-A1 | Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using The Same | PHARMAIN CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-8563527-B2 | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same | PHARMAIN CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| CN-101365490-B | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | PHARMAIN CORP | 2012-11-28 | — | — | CN | disclosed |
| US-20090053169-A1 | Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same | PHARMAIN CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| CN-101365490-A | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same | PHARMAIN CORP (US) | 2009-02-11 | — | — | CN | disclosed |
| EP-1971372-A2 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | Pharmain, Ltd. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007076371-A2 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMAIN CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | PHARMALN LTD. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141145-A1 | HYDROPHOBIC CORE CARRIER COMPOSITIONS FOR DELIVERY OF THERAPEUTIC AGENTS, METHODS OF MAKING AND USING THE SAME | CD44, HDGF, MTDH | ALDH1A1 2090/4885FKBP5 2691/4885TDP1 2606/4885 |
| US-20090053169-A1 | Oligonucleotide Core Carrier Compositions for Delivery of Nucleic Acid-Containing Therapeutic Agents, Methods of Making and Using the Same | DCLRE1B, POLRMT, POLN | ALDH1A1 2795/4885FKBP5 2837/4885TDP1 326/4885 |
| US-20170368190-A1 | Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same | CD44, HDGF, MTDH | ALDH1A1 2090/4885FKBP5 2691/4885TDP1 2606/4885 |
| US-20140154203-A1 | Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using The Same | CD44, HDGF, MTDH | ALDH1A1 2090/4885FKBP5 2691/4885TDP1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.